A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia
Qian Zhang, Morgan Hresko, Lora K. Picton, Leon Su, Michael J. Hollander, Selene Nuñez-Cruz, Zheng Zhang, Charles‐Antoine Assenmacher, Jonathan T. Sockolosky, K. Christopher García, Michael C. Milone
Abstract
-hIL-2 administration initiated at the time of leukemic relapse after CAR T cell therapy can rescue an otherwise failed antileukemic response. These data highlight the potential of combining an orthogonal cytokine approach with T cell–based immunotherapies to augment the antitumor efficacy of engineered T cells.
Topics & Concepts
Chimeric antigen receptorCytokineT cellCancer researchAdoptive cell transferCD19ImmunotherapyCytokine release syndromeCytotoxic T cellInterleukin 2ImmunologyLeukemiaBiologyAntigenImmune systemIn vitroBiochemistryCAR-T cell therapy researchViral Infectious Diseases and Gene Expression in InsectsVirus-based gene therapy research